Investigation of serum adropin levels and its relationship with hypothalamic atrophy in patients with multiple sclerosis

Basit Öğe Kaydı
dc.contributor.authorDemirdogen, Filiz
dc.contributor.authorAkdag, Turan
dc.contributor.authorGunduz, Zahide Betuel
dc.contributor.authorOdabas, Faruk Omer
dc.date.accessioned2024-02-23T14:13:18Z
dc.date.available2024-02-23T14:13:18Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractObjective Adropin is expressed in vascular endothelial cells and regulates nitric oxide (NO) bioavailability by upregulating nitric oxide. In recent years, some studies have revealed its relationship with the pathogenesis of multiple sclerosis (MS). Our aim in this study is to determine serum adropin levels in MS patients and to investigate adropin levels's relationship with hypothalamic atrophy.Methods A total of 80 people, 40 of whom had MS and 40 of whom were healthy volunteers, were included in the study. Serum samples were taken from all participants. Hypothalamus and pituitary diameters were calculated from magnetic resonance imaging of MS patients. The relationship between serum adropin levels and demographic characteristics, Expanded Disability Status Scale (EDSS), and hypothalamic atrophy were evaluated.Results The levels of adropin were 0.85 +/- 0.14 ng/mL in patients with MS and 2.96 ng/mL +/- 0.285 ng/mL in the healthy controls. MS patients had significantly lower levels of adropin than the healthy controls (p = 0.003). Adropin has the highest diagnostic value (AUC=0.874, (95% CI, 0,800-0,947) as cut-off value (838.00), sensitivity (80.43%) and specificity (70.64%) in the MS group. In the study, serum adropin levels were not significantly correlated with 3 ventricle diameter (3VD) and pituitary diameter (PD) size (p = 0,968) and no significant relationships were determined between adropin and other clinical parameters.Conclusion As a potential diagnostic marker, adropin levels were significantly lower in MS patients than in those without. Comprehensive studies are needed to verify this entity.en_US
dc.identifier.doi10.1016/j.msard.2022.103948
dc.identifier.issn2211-0348
dc.identifier.issn2211-0356
dc.identifier.pmid35843143en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.msard.2022.103948
dc.identifier.urihttps://hdl.handle.net/20.500.12452/12371
dc.identifier.volume66en_US
dc.identifier.wosWOS:000829478300004en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofMultiple Sclerosis And Related Disordersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMultiple Sclerosisen_US
dc.subjectAdropinen_US
dc.subjectHypothalamic Atrophyen_US
dc.subjectPituitary Atrophyen_US
dc.titleInvestigation of serum adropin levels and its relationship with hypothalamic atrophy in patients with multiple sclerosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu